# Bioventus Receives Dual FDA 510(k) Clearances for TalisMann and StimTrial Peripheral Nerve Stimulation Devices

> fda · REPORTED · 2025-07-30

Bioventus received FDA 510(k) clearances for both its TalisMann and StimTrial peripheral nerve stimulation products for chronic pain management on July 30, 2025, expanding its PNS portfolio in a market expected to exceed $500 million by 2029.

- Company: Bioventus
- Sector: medical devices
- Primary source: https://www.sec.gov/Archives/edgar/data/0001665988/000166598825000013/exhibit991pressrelease-fda.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.